FAP, May 12 / PRNewswire-FirstCall-Asianet /-- recently, the company received a notice of acceptance issued by the State Drug Administration, and the application for clinical trials of EYP-1901 vitreous implants jointly declared by the company and EyePoint (NASDAQ:EYPT) has been accepted by the State Drug Administration.